AR098328A1 - Terapia de combinación de un anticuerpo anti cd20 con un inhibidor de btk - Google Patents

Terapia de combinación de un anticuerpo anti cd20 con un inhibidor de btk

Info

Publication number
AR098328A1
AR098328A1 ARP140104176A ARP140104176A AR098328A1 AR 098328 A1 AR098328 A1 AR 098328A1 AR P140104176 A ARP140104176 A AR P140104176A AR P140104176 A ARP140104176 A AR P140104176A AR 098328 A1 AR098328 A1 AR 098328A1
Authority
AR
Argentina
Prior art keywords
antibody
combination therapy
btk inhibitor
type
afucosylated
Prior art date
Application number
ARP140104176A
Other languages
English (en)
Original Assignee
Ono Pharmaceutical Co
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co, Hoffmann La Roche filed Critical Ono Pharmaceutical Co
Publication of AR098328A1 publication Critical patent/AR098328A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Abstract

La presente solicitud se refiere a la terapia de combinación de un anticuerpo anti-CD20 con un inhibidor de BTK para el tratamiento del cáncer, especialmente a la terapia de combinación de cánceres que expresan CD20 con un anticuerpo anti-CD20 de tipo I o un anticuerpo B-Ly1 humanizado afucosilado y un inhibidor de BTK. Reivindicación 2: El anticuerpo de acuerdo con la reivindicación 1, caracterizado por que dicho anticuerpo anti-CD20 es un anticuerpo anti-CD20 de tipo I o un anticuerpo anti-CD20 afucosilado con una cantidad de fucosa del 60% o menor de la cantidad total de oligosacáridos (azúcares) en Asn297.
ARP140104176A 2013-11-07 2014-11-06 Terapia de combinación de un anticuerpo anti cd20 con un inhibidor de btk AR098328A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13192006 2013-11-07

Publications (1)

Publication Number Publication Date
AR098328A1 true AR098328A1 (es) 2016-05-26

Family

ID=49552219

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140104176A AR098328A1 (es) 2013-11-07 2014-11-06 Terapia de combinación de un anticuerpo anti cd20 con un inhibidor de btk

Country Status (21)

Country Link
US (2) US20150125446A1 (es)
EP (1) EP3066126B1 (es)
JP (1) JP6478989B2 (es)
KR (1) KR101874215B1 (es)
CN (3) CN114632158A (es)
AR (1) AR098328A1 (es)
AU (1) AU2014345712B2 (es)
BR (1) BR112016010271A2 (es)
CA (1) CA2926893C (es)
ES (1) ES2728350T3 (es)
HK (1) HK1222803A1 (es)
IL (1) IL244960B (es)
MX (1) MX2016005801A (es)
MY (1) MY178726A (es)
NZ (1) NZ718792A (es)
PH (1) PH12016500839A1 (es)
PL (1) PL3066126T3 (es)
RU (1) RU2727650C2 (es)
TR (1) TR201907240T4 (es)
TW (1) TWI524899B (es)
WO (1) WO2015067586A2 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ602176A (en) 2010-03-12 2015-01-30 Immunogen Inc Cd37-binding molecules and immunoconjugates thereof
PT2578585T (pt) 2010-05-31 2016-09-23 Ono Pharmaceutical Co Derivado de purinona como inibidor da quinase btk
RS55542B1 (sr) 2011-11-29 2017-05-31 Ono Pharmaceutical Co Purinonski derivati hlorovodonika
WO2015146159A1 (en) 2014-03-25 2015-10-01 Ono Pharmaceutical Co., Ltd. Prophylactic agent and/or therapeutic agent for diffuse large b-cell lymphoma
HUE049175T2 (hu) * 2014-09-23 2020-09-28 Hoffmann La Roche Eljárás anti-CD79b immunkonjugátumok alkalmazására
WO2016163531A1 (ja) 2015-04-09 2016-10-13 小野薬品工業株式会社 プリノン誘導体の製造方法
KR20180011315A (ko) 2015-06-08 2018-01-31 데비오팜 인터네셔날 에스 에이 항-cd37 면역접합체 및 항-cd20 항체 조합
RS62986B1 (sr) 2015-06-24 2022-03-31 Hoffmann La Roche Antitela na transferinski receptor sa prilagođenim afinitetom
CN108699144B (zh) 2015-08-28 2022-07-19 德彪发姆国际有限公司 用于检测cd37的抗体和测定
WO2017059224A2 (en) * 2015-10-01 2017-04-06 Gilead Sciences, Inc. Combination of a btk inhibitor and a checkpoint inhibitor for treating cancers
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
CA3000746A1 (en) * 2015-10-02 2017-04-06 Gilead Sciences, Inc. Combinations of the btk inhibitor gs-4059 with inhibitors selected from a jak, ask1, brd and/or mmp9 inhibitor to treat cancer, allergic disorders, autoimmune diseases or inflammatory diseases
TWI819458B (zh) 2015-10-02 2023-10-21 瑞士商赫孚孟拉羅股份公司 雙特異性抗‐人類cd20/人類轉鐵蛋白受體抗體及使用方法
US11278629B2 (en) 2016-11-02 2022-03-22 Debiopharm International, S.A. Methods for improving anti-CD37 immunoconjugate therapy
WO2018106931A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
EP4108183A1 (en) 2017-03-30 2022-12-28 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
JP2020528061A (ja) * 2017-07-26 2020-09-17 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ＢＥＴ阻害剤、Ｂｃｌ−２阻害剤及び抗ＣＤ２０抗体を用いた併用療法
CA3071618A1 (en) 2017-08-08 2019-02-14 F. Hoffmann-La Roche Ag Obinutuzumab treatment of a dlbcl patient subgroup
WO2019246317A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease or condition in a tissue originating from the endoderm
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
WO2020106757A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
EP3870261B1 (en) 2019-12-13 2024-01-31 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1034298B1 (en) * 1997-12-05 2011-11-02 The Scripps Research Institute Humanization of murine antibody
NZ581541A (en) * 2002-10-17 2011-07-29 Genmab As Human monoclonal antibodies against CD20
EP2178916B1 (en) * 2007-07-31 2014-12-17 Regeneron Pharmaceuticals, Inc. Human antibodies to human cd20 and method of using thereof
PT2578585T (pt) * 2010-05-31 2016-09-23 Ono Pharmaceutical Co Derivado de purinona como inibidor da quinase btk
EA201892766A1 (ru) * 2011-10-19 2019-08-30 Фармасайкликс Элэлси ПРИМЕНЕНИЕ ИНГИБИТОРОВ ТИРОЗИНКИНАЗЫ БРУТОНА (Btk)
US20130302274A1 (en) * 2011-11-25 2013-11-14 Roche Glycart Ag Combination therapy
RS55542B1 (sr) * 2011-11-29 2017-05-31 Ono Pharmaceutical Co Purinonski derivati hlorovodonika
TW201427667A (zh) * 2012-11-20 2014-07-16 Celgene Avilomics Res Inc 治療和布魯頓（ｂｒｕｔｏｎ’ｓ）酪胺酸激酶相關之疾病或失調的方法

Also Published As

Publication number Publication date
NZ718792A (en) 2020-05-29
RU2016122232A3 (es) 2018-06-18
EP3066126B1 (en) 2019-03-27
CA2926893A1 (en) 2015-05-14
WO2015067586A3 (en) 2015-07-30
WO2015067586A2 (en) 2015-05-14
US20150125446A1 (en) 2015-05-07
BR112016010271A2 (pt) 2017-10-03
IL244960A0 (en) 2016-05-31
JP6478989B2 (ja) 2019-03-06
EP3066126A2 (en) 2016-09-14
AU2014345712B2 (en) 2019-10-17
RU2016122232A (ru) 2017-12-08
CN105792846A (zh) 2016-07-20
AU2014345712A1 (en) 2016-05-05
JP2016536298A (ja) 2016-11-24
HK1222803A1 (zh) 2017-07-14
CA2926893C (en) 2022-04-12
KR101874215B1 (ko) 2018-07-03
KR20160079869A (ko) 2016-07-06
RU2727650C2 (ru) 2020-07-22
TR201907240T4 (tr) 2019-06-21
US20200171153A1 (en) 2020-06-04
PL3066126T3 (pl) 2019-08-30
MY178726A (en) 2020-10-20
TWI524899B (zh) 2016-03-11
PH12016500839A1 (en) 2016-06-13
MX2016005801A (es) 2016-11-29
CN114632158A (zh) 2022-06-17
ES2728350T3 (es) 2019-10-23
CN113995843A (zh) 2022-02-01
IL244960B (en) 2021-08-31
TW201521767A (zh) 2015-06-16

Similar Documents

Publication Publication Date Title
AR098328A1 (es) Terapia de combinación de un anticuerpo anti cd20 con un inhibidor de btk
AR077866A1 (es) Terapia de combinacion de un anticuerpo cd20 afucosilado y bendamustina
AR082693A1 (es) Terapia de combinacion de un anticuerpo anti-cd20 afucosilado con un anticuerpo anti-vegf
CL2018000222A1 (es) Nueva combinación para el uso en el tratamiento del cáncer
CR20170529A (es) Terapia combinada de un anticuerpo anti-cd-20 con un inhibidor de bcl-2 y un inhibidor de mdm2.
CL2017002241A1 (es) Método de tratamiento de cáncer asociado con una mutación de ras
CR20150376A (es) Compuestos sustituidos de pirrolopirimidina, compuestos de los mismos y metodos de tratamiento con los mismos
ES2765949T8 (es) Terapia que involucra anticuerpos contra la claudina 18.2 para el tratamiento del cáncer
AR096184A1 (es) Terapia de combinación de un anticuerpo para cd20 afucosilado con un conjugado de anticuerpos para cd22-fármaco
BR112017026027A2 (pt) combinações de imunoconjugado anti-cd37 e anticorpo anti-cd20
AR096183A1 (es) Terapia de combinación de un anticuerpo para cd20 afucosilado con un conjugado de anticuerpo para cd79b-fármaco
AR077867A1 (es) Terapia combinatoria de un anticuerpo cd20 afucosilado con fludarabina y/o mitoxantrona
CU20150128A7 (es) Conjugados fármaco-anticuerpo
CR20150216A (es) Composiciones y métodos para tratar proteinopatías
UY35399A (es) Conjugados de fármacos con anticuerpos
BR112015019995A2 (pt) Combinação terapêutica envolvendo anticorpos contra claudina 18.2 para tratamento de câncer
MX2016002974A (es) Eteres de arilo y sus usos.
AR104664A1 (es) Conjugados de fármacos con anticuerpos contra la cadherina 6 (anti-cdh6)
NI201500150A (es) TRATAMIENTO DE CÁNCER CON DIHIDROPIRAZINO-PIRAZINAS×Se proporcionan en la presente método
NI201400112A (es) Tratamiento del cáncer con inhibidores tor cinasa
MX2013006739A (es) Terapia combinada de anticuerpo cd20 afucosilado con inhibidor de mdm2.
BR112017028287A2 (pt) Combinação do inibidor hdac e anticorpido anti-pd- l1 para o tratamento do câncer
CL2019000585A1 (es) Combinación de un anticuerpo anti-cd20, inhibidor pi3 kinase-delta y anticuerdo anti-pd-1 o anti-pd-l1 para el tratamiento de cánceres hematológicos.
CL2017000050A1 (es) Terapia de combinación para el cáncer
TR201905813T4 (tr) Dağıtma kapsülü.

Legal Events

Date Code Title Description
FB Suspension of granting procedure